[HTML][HTML] Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

A Durrbach, JM Pestana, T Pearson, F Vincenti… - American Journal of …, 2010 - Elsevier
Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft
dysfunction/loss, and may benefit from immunosuppression that avoids calcineurin inhibitor
(CNI) nephrotoxicity. Belatacept, a selective costimulation blocker, may preserve renal
function and improve long‐term outcomes versus CNIs. BENEFIT‐EXT (Belatacept
Evaluation of Nephroprotection and Efficacy as First‐line Immunosuppression Trial—
EXTended criteria donors) is a 3‐year, Phase III study that assessed a more (MI) or less …